An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
Abstract Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy a...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-05-01
|
| Series: | Drugs in R&D |
| Online Access: | https://doi.org/10.1007/s40268-025-00509-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471338565074944 |
|---|---|
| author | Derek E. Murrell Benjamin C. Kennard Maria E. Bertoni David B. Cluck Jonathan P. Moorman Stacy D. Brown Kesheng Wang Michelle M. Duffourc Sam Harirforoosh |
| author_facet | Derek E. Murrell Benjamin C. Kennard Maria E. Bertoni David B. Cluck Jonathan P. Moorman Stacy D. Brown Kesheng Wang Michelle M. Duffourc Sam Harirforoosh |
| author_sort | Derek E. Murrell |
| collection | DOAJ |
| description | Abstract Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy and tolerability among patients. This study sought to investigate the relationship, if any, of single nucleotide polymorphisms (SNPs) and selected clinical parameters. Methods The study population, predominantly Caucasian males with a median age of 53.0 years [interquartile range 46.0–59.0], was assayed for genetic variations using an iPLEX ADME PGx Pro v1.0 Panel. Results Although several SNP relationships were found with both forms of tenofovir, many of the reported SNPs were displayed only in the comprehensive regimen grouping, making it difficult to distinguish between the two prodrug forms. Conclusions Being an exploratory study, the findings of this substudy serve as potential avenues for further research. |
| format | Article |
| id | doaj-art-0b737ba6cc5c4e50af40147d1f6f19c3 |
| institution | Kabale University |
| issn | 1174-5886 1179-6901 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Drugs in R&D |
| spelling | doaj-art-0b737ba6cc5c4e50af40147d1f6f19c32025-08-20T03:24:52ZengAdis, Springer HealthcareDrugs in R&D1174-58861179-69012025-05-0125215316010.1007/s40268-025-00509-6An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil FumarateDerek E. Murrell0Benjamin C. Kennard1Maria E. Bertoni2David B. Cluck3Jonathan P. Moorman4Stacy D. Brown5Kesheng Wang6Michelle M. Duffourc7Sam Harirforoosh8Department of Pharmaceutical Sciences, Gatton College of Pharmacy, East Tennessee State UniversityGatton College of Pharmacy, East Tennessee State UniversityGatton College of Pharmacy, East Tennessee State UniversityDepartment of Pharmacy Practice, Gatton College of Pharmacy, East Tennessee State UniversityDepartment of Internal Medicine, Quillen College of Medicine, East Tennessee State UniversityDepartment of Pharmaceutical Sciences, Gatton College of Pharmacy, East Tennessee State UniversityDepartment of Biobehavioral Health and Nursing Science, College of Nursing, University of South CarolinaDepartment of Biomedical Sciences, Quillen College of Medicine, East Tennessee State UniversityDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman UniversityAbstract Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy and tolerability among patients. This study sought to investigate the relationship, if any, of single nucleotide polymorphisms (SNPs) and selected clinical parameters. Methods The study population, predominantly Caucasian males with a median age of 53.0 years [interquartile range 46.0–59.0], was assayed for genetic variations using an iPLEX ADME PGx Pro v1.0 Panel. Results Although several SNP relationships were found with both forms of tenofovir, many of the reported SNPs were displayed only in the comprehensive regimen grouping, making it difficult to distinguish between the two prodrug forms. Conclusions Being an exploratory study, the findings of this substudy serve as potential avenues for further research.https://doi.org/10.1007/s40268-025-00509-6 |
| spellingShingle | Derek E. Murrell Benjamin C. Kennard Maria E. Bertoni David B. Cluck Jonathan P. Moorman Stacy D. Brown Kesheng Wang Michelle M. Duffourc Sam Harirforoosh An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate Drugs in R&D |
| title | An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate |
| title_full | An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate |
| title_fullStr | An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate |
| title_full_unstemmed | An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate |
| title_short | An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate |
| title_sort | exploratory pharmacogenetic pilot study of two reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate |
| url | https://doi.org/10.1007/s40268-025-00509-6 |
| work_keys_str_mv | AT derekemurrell anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT benjaminckennard anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT mariaebertoni anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT davidbcluck anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT jonathanpmoorman anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT stacydbrown anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT keshengwang anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT michellemduffourc anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT samharirforoosh anexploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT derekemurrell exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT benjaminckennard exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT mariaebertoni exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT davidbcluck exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT jonathanpmoorman exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT stacydbrown exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT keshengwang exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT michellemduffourc exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate AT samharirforoosh exploratorypharmacogeneticpilotstudyoftworeversetranscriptaseinhibitorstenofoviralafenamidefumarateandtenofovirdisoproxilfumarate |